Oldsmar, Fla., July 20 /PRNewswire-FirstCall/ --Women today have a number of options when it comes to protecting their future health and possibly that of their families. Banking stem cells found in menstrual blood is one way in which women are looking to safeguard against potential future illnesses, conditions or injuries. Menstrual blood has been shown to contain self-renewing stem cells that may be stored for potential treatments in the future. A Florida-based company, Cryo-Cell International, Inc. offers C'elle, a service that empowers women to collect and preserve stem cells harvested from their own menstrual blood. Featured in a recent healthcare segment on ABC Action News in Tampa Bay, the promise of C'elle technology offers insightful perspectives from a C'elle client and from a stem cell researcher who is exploring development of Cryo-Cell's proprietary cutting edge technology for a potential neurological application.
Menstrual stem cells (MenSCs) potentially offer compelling advantages over stem cells obtained from other sources because they can be easily obtained from women in a painless, non-invasive manner, and they are an exact match for the woman donor and therefore the patient's rejection of tissue may be avoided. Since menstrual stem cells are harvested from a source that would otherwise be regarded as biological waste, there are no ethical questions that are associated with embryonic stem cells.
"We are clearly excited as Cryo-Cell continues to build a significant pipeline of strong research partnerships that are independently funded and that may possibly lead to breakthrough therapies for future human clinical studies," said Mercedes A. Walton, Chairman and CEO of Cryo-Cell. "We are also pleased to empower women with the opportunity to harvest and cryopreserve their own stem cells today for possible utilization in the future."
The C'elle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit http://www.Celle.com
SOURCE Cryo-Cell International, Inc.
CONTACT: General Media Inquiries, Kristin O'Neill, +1-312-233-1295,
Kristin.Oneill@edelman.com; or Financial Media Inquiries, Dianne Will,
Investor Relations, Cryo-Cell International, Inc., +1-518-398-6222,
Web site: http://www.cryo-cell.com/